T863 is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells. T863 causes weight loss, reduction in serum and liver triglycerides, and improved insulin sensitivity in obese mice.
T863 is an orally active, selective and potent DGAT1 inhibitor.
Foamy macrophages, which have prominent lipid droplets (LDs), are found in a variety of disease states. Toll-like receptor agonists drive triacylglycerol (TG)-rich LD development in macrophages. Here we explore the basis and significance of this process. Our findings indicate that
bioRxiv : the preprint server for biology (2020-08-04)
Therapeutics targeting replication of SARS coronavirus 2 (SARS-CoV-2) are urgently needed. Coronaviruses rely on host membranes for entry, establishment of replication centers and egress. Compounds targeting cellular membrane biology and lipid biosynthetic pathways have previously shown promise as antivirals and
Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state
Magtanong L, et al.
Cell Chemical Biology, 26(3), 420-432 (2019)
DGAT1-dependent lipid droplet biogenesis protects mitochondrial function during starvation-induced autophagy
Nguyen TB, et al.
Developmental Cell, 42(1), 9-21 (2017)
Lipid droplet formation in Mycobacterium tuberculosis infected macrophages requires IFN gamma/HIF-1alpha signaling and supports host defense
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
